Laurus Labs Ltd.
LAURUSLABSHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
33 transcript(s)/analyst meet(s) served; 5 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 33 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20191107 | 2019-09-30 | yes | |
| TRANSCRIPT | 20200210 | 2019-12-31 | yes | |
| TRANSCRIPT | 20200509 | 2020-03-31 | yes | |
| TRANSCRIPT | 20200805 | 2020-06-30 | yes | |
| TRANSCRIPT | 20201109 | 2020-09-30 | yes | |
| TRANSCRIPT | 20211102 | 2020-09-30 | yes | |
| TRANSCRIPT | 20210205 | 2020-12-31 | yes | |
| TRANSCRIPT | 20210505 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210803 | 2021-06-30 | yes | |
| TRANSCRIPT | 20220202 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220505 | 2022-03-31 | yes | |
| COVER_LETTER | 20221021 | 2022-09-30 | no | |
| TRANSCRIPT | 20221025 | 2022-09-30 | yes | |
| COVER_LETTER | 20230130 | 2022-12-31 | no | |
| TRANSCRIPT | 20230204 | 2022-12-31 | yes | |
| TRANSCRIPT | 20220802 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230503 | 2023-03-31 | yes | |
| COVER_LETTER | 20230727 | 2023-06-30 | no | |
| TRANSCRIPT | 20230801 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231025 | 2023-09-30 | yes | |
| COVER_LETTER | 20240124 | 2023-12-31 | no | |
| TRANSCRIPT | 20240130 | 2023-12-31 | yes | |
| COVER_LETTER | 20240425 | 2024-03-31 | no | |
| TRANSCRIPT | 20240430 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240729 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241029 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250129 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250428 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250729 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251028 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260128 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260505 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260730 | 2026-06-30 | yes |
LAURUSLABS
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 2,026.20 |
| 52-week range | 832.3 – 2034.0 |
| Return 1M | 8.57% |
| Return 3M | 39.74% |
| Return 1Y | 122.72% |
| Return 3Y | 421.14% |
| Return 5Y | 232.08% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 2,026.00 |
| Other income | 9.00 |
| Total income | 2,035.00 |
| Cost of materials consumed | 786.00 |
| Purchases of stock-in-trade | 35.00 |
| Changes in inventories | -65.00 |
| Employee benefit expense | 259.00 |
| Finance costs | 42.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.27 | -0.00 |
| institutions foreign | 0.28 | 0.02 |
| institutions domestic | 0.14 | -0.00 |
| mutual funds | 0.10 | -0.01 |
| public | 0.73 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2024-03-31 | 5 |
| TRANSCRIPT | 2026-06-30 | 28 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,576.00 | 1,545.00 | 1,381.00 | 1,182.00 | 1,224.00 | 1,195.00 | 1,440.00 | 1,195.00 | 1,224.00 | 1,415.00 | 1,720.00 | 1,570.00 | 1,653.00 | 1,778.00 | 1,812.00 | 2,026.00 |
| Other income | 1.00 | 1.00 | 2.00 | 4.00 | 2.00 | 2.00 | 19.00 | 3.00 | 5.00 | 9.00 | 59.00 | 10.00 | 27.00 | 6.00 | 12.00 | 9.00 |
| Total income | 1,577.00 | 1,546.00 | 1,383.00 | 1,185.00 | 1,226.00 | 1,197.00 | 1,458.00 | 1,197.00 | 1,228.00 | 1,424.00 | 1,779.00 | 1,580.00 | 1,680.00 | 1,784.00 | 1,823.00 | 2,035.00 |
| Cost of materials consumed | 779.00 | 582.00 | 476.00 | 523.00 | 673.00 | 634.00 | 591.00 | 572.00 | 577.00 | 653.00 | 626.00 | 599.00 | 677.00 | 725.00 | 793.00 | 786.00 |
| Purchases of stock-in-trade | 44.00 | 52.00 | 5.00 | 26.00 | 26.00 | 18.00 | 41.00 | 23.00 | 26.00 | 35.00 | 22.00 | 38.00 | 31.00 | 55.00 | 48.00 | 35.00 |
| Changes in inventories | -116.00 | 86.00 | 213.00 | 34.00 | -119.00 | -106.00 | 90.00 | -58.00 | -54.00 | -78.00 | 134.00 | -1.00 | -44.00 | -86.00 | -141.00 | -65.00 |
| Employee benefit expense | 147.00 | 147.00 | 134.00 | 160.00 | 164.00 | 155.00 | 161.00 | 174.00 | 179.00 | 189.00 | 178.00 | 215.00 | 216.00 | 229.00 | 236.00 | 259.00 |
| Finance costs | 40.00 | 43.00 | 53.00 | 39.00 | 42.00 | 51.00 | 50.00 | 49.00 | 53.00 | 58.00 | 56.00 | 52.00 | 40.00 | 39.00 | 40.00 | 42.00 |
| Depreciation and amortisation | 82.00 | 84.00 | 87.00 | 91.00 | 93.00 | 98.00 | 102.00 | 106.00 | 108.00 | 106.00 | 110.00 | 117.00 | 120.00 | 121.00 | 122.00 | 124.00 |
| Other expenses | 273.00 | 275.00 | 267.00 | 271.00 | 292.00 | 313.00 | 315.00 | 313.00 | 318.00 | 331.00 | 339.00 | 335.00 | 371.00 | 374.00 | 364.00 | 373.00 |
| Total expenses | 1,249.00 | 1,268.00 | 1,235.00 | 1,145.00 | 1,172.00 | 1,163.00 | 1,351.00 | 1,179.00 | 1,205.00 | 1,294.00 | 1,467.00 | 1,356.00 | 1,411.00 | 1,457.00 | 1,462.00 | 1,554.00 |
| Profit before exceptional items and tax | 328.00 | 278.00 | 147.00 | 41.00 | 54.00 | 35.00 | 107.00 | 18.00 | 23.00 | 131.00 | 312.00 | 224.00 | 270.00 | 327.00 | 361.00 | 481.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 328.00 | 278.00 | 147.00 | 41.00 | 54.00 | 35.00 | 107.00 | 18.00 | 23.00 | 131.00 | 312.00 | 224.00 | 270.00 | 327.00 | 361.00 | 481.00 |
| Current tax | 93.00 | 74.00 | 12.00 | 16.00 | 15.00 | 18.00 | 43.00 | 18.00 | 23.00 | 35.00 | 80.00 | 60.00 | 88.00 | 71.00 | 78.00 | 135.00 |
| Deferred tax | 1.00 | 0.00 | 28.00 | -4.00 | -1.00 | -9.00 | -11.00 | -12.00 | -18.00 | 5.00 | -2.00 | 3.00 | -12.00 | 2.00 | 1.00 | -16.00 |
| Tax expense | 94.00 | 75.00 | 40.00 | 12.00 | 15.00 | 9.00 | 32.00 | 6.00 | 5.00 | 40.00 | 78.00 | 63.00 | 76.00 | 73.00 | 79.00 | 119.00 |
| Profit for the period | 233.00 | 203.00 | 105.00 | 27.00 | 37.00 | 23.00 | 75.00 | 13.00 | 20.00 | 93.00 | 233.00 | 162.00 | 194.00 | 252.00 | 282.00 | 362.00 |
| Profit attributable to owners | 233.00 | 230.00 | 103.00 | 25.00 | 37.00 | 23.00 | 76.00 | 13.00 | 20.00 | 92.00 | 234.00 | 163.00 | 195.00 | 252.00 | 279.00 | 368.00 |
| Profit attributable to non-controlling interests | 1.00 | -0.00 | 2.00 | 2.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 1.00 | -1.00 | -1.00 | -0.00 | 0.00 | 3.00 | -6.00 |
| Other comprehensive income | -5.00 | -0.00 | 0.00 | -2.00 | -2.00 | -1.00 | 2.00 | 0.00 | -0.00 | -1.00 | -2.00 | -1.00 | -6.00 | -2.00 | 2.00 | -2.00 |
| Total comprehensive income | 229.00 | 202.00 | 105.00 | 24.00 | 35.00 | 22.00 | 77.00 | 13.00 | 20.00 | 91.00 | 231.00 | 161.00 | 189.00 | 250.00 | 284.00 | 360.00 |
| Earnings per share, basic | 4.33 | 3.78 | 1.90 | 0.46 | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.34 | 3.02 | 3.61 | 4.67 | 5.17 | 6.81 |
| Earnings per share, diluted | 4.32 | 3.76 | 1.90 | 0.46 | 0.68 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.65 | 5.17 | 6.80 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,292.00 | 2,832.00 | 4,814.00 | 4,936.00 | 6,041.00 | 5,041.00 | 5,554.00 | 6,813.00 |
| Other income | 16.00 | 6.00 | 24.00 | 15.00 | 6.00 | 26.00 | 75.00 | 55.00 |
| Total income | 2,308.00 | 2,838.00 | 4,837.00 | 4,951.00 | 6,047.00 | 5,067.00 | 5,629.00 | 6,868.00 |
| Cost of materials consumed | 1,245.00 | 1,614.00 | 2,359.00 | 2,269.00 | 2,597.00 | 2,422.00 | 2,429.00 | 2,794.00 |
| Purchases of stock-in-trade | 22.00 | 16.00 | 96.00 | 146.00 | 156.00 | 111.00 | 105.00 | 173.00 |
| Changes in inventories | -32.00 | -216.00 | -297.00 | -221.00 | 22.00 | -101.00 | -56.00 | -271.00 |
| Employee benefit expense | 289.00 | 345.00 | 434.00 | 502.00 | 581.00 | 640.00 | 720.00 | 895.00 |
| Finance costs | 88.00 | 90.00 | 68.00 | 102.00 | 165.00 | 183.00 | 216.00 | 171.00 |
| Depreciation and amortisation | 164.00 | 187.00 | 205.00 | 251.00 | 324.00 | 385.00 | 430.00 | 480.00 |
| Other expenses | 411.00 | 509.00 | 671.00 | 818.00 | 1,093.00 | 1,191.00 | 1,301.00 | 1,444.00 |
| Total expenses | 2,188.00 | 2,544.00 | 3,536.00 | 3,867.00 | 4,938.00 | 4,831.00 | 5,145.00 | 5,686.00 |
| Profit before exceptional items and tax | 120.00 | 294.00 | 1,301.00 | 1,084.00 | 1,109.00 | 236.00 | 484.00 | 1,182.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 120.00 | 294.00 | 1,301.00 | 1,084.00 | 1,109.00 | 236.00 | 484.00 | 1,182.00 |
| Current tax | 25.00 | 54.00 | 338.00 | 254.00 | 290.00 | 93.00 | 157.00 | 298.00 |
| Deferred tax | 1.00 | -15.00 | -20.00 | -3.00 | 22.00 | -25.00 | -27.00 | -5.00 |
| Tax expense | 26.00 | 38.00 | 317.00 | 251.00 | 312.00 | 68.00 | 130.00 | 292.00 |
| Profit for the period | 94.00 | 255.00 | 984.00 | 832.00 | 793.00 | 162.00 | 358.00 | 890.00 |
| Profit attributable to owners | 0.00 | 0.00 | 0.00 | 828.00 | 790.00 | 161.00 | 358.00 | 889.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 5.00 | 3.00 | 2.00 | 0.00 | 1.00 |
| Other comprehensive income | -4.00 | -11.00 | 5.00 | 1.00 | -6.00 | -3.00 | -4.00 | -6.00 |
| Total comprehensive income | 90.00 | 244.00 | 989.00 | 833.00 | 788.00 | 159.00 | 355.00 | 884.00 |
| Earnings per share, basic | 8.83 | 23.93 | 18.36 | 15.42 | 14.69 | 2.98 | 6.65 | 16.47 |
| Earnings per share, diluted | 8.80 | 23.93 | 18.28 | 15.35 | 14.64 | 2.97 | 6.64 | 16.45 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 8,056.00 | 7,660.00 | 8,058.00 | 8,387.00 | 8,729.00 | 9,336.00 | 9,415.00 | 10,511.00 |
| Non-current assets | 3,883.00 | 4,199.00 | 4,390.00 | 4,552.00 | 4,610.00 | 5,003.00 | 5,224.00 | 5,682.00 |
| Current assets | 4,173.00 | 3,462.00 | 3,668.00 | 3,835.00 | 4,120.00 | 4,332.00 | 4,192.00 | 4,829.00 |
| Property, plant and equipment | 2,835.00 | 3,016.00 | 3,315.00 | 3,446.00 | 3,401.00 | 3,668.00 | 3,800.00 | 3,873.00 |
| Capital work-in-progress | 471.00 | 551.00 | 444.00 | 423.00 | 521.00 | 458.00 | 541.00 | 773.00 |
| Goodwill | 246.00 | 246.00 | 246.00 | 246.00 | 246.00 | 246.00 | 246.00 | 246.00 |
| Other intangible assets | 13.00 | 13.00 | 12.00 | 19.00 | 17.00 | 19.00 | 18.00 | 18.00 |
| Inventories | 2,261.00 | 1,685.00 | 1,866.00 | 1,845.00 | 2,107.00 | 1,937.00 | 2,021.00 | 2,342.00 |
| Trade receivables | 1,732.00 | 1,580.00 | 1,549.00 | 1,663.00 | 1,750.00 | 2,007.00 | 1,859.00 | 2,155.00 |
| Cash and cash equivalents | 50.00 | 46.00 | 67.00 | 139.00 | 43.00 | 100.00 | 50.00 | 113.00 |
| Total equity and liabilities | 8,056.00 | 7,660.00 | 8,058.00 | 8,387.00 | 8,729.00 | 9,336.00 | 9,415.00 | 10,511.00 |
| Equity | 3,773.00 | 4,049.00 | 4,043.00 | 4,116.00 | 4,144.00 | 4,603.00 | 4,934.00 | 5,431.00 |
| Equity share capital | 107.00 | 108.00 | 108.00 | 108.00 | 108.00 | 108.00 | 108.00 | 108.00 |
| Other equity | 3,656.00 | 3,930.00 | 3,922.00 | 4,003.00 | 4,026.00 | 4,365.00 | 4,697.00 | 5,192.00 |
| Total liabilities | 4,283.00 | 3,612.00 | 4,015.00 | 4,271.00 | 4,585.00 | 4,733.00 | 4,482.00 | 5,080.00 |
| Non-current liabilities | 943.00 | 1,179.00 | 1,069.00 | 1,159.00 | 1,126.00 | 1,193.00 | 1,307.00 | 1,444.00 |
| Current liabilities | 3,340.00 | 2,432.00 | 2,945.00 | 3,112.00 | 3,459.00 | 3,540.00 | 3,175.00 | 3,635.00 |
| Borrowings, non-current | 540.00 | 761.00 | 653.00 | 798.00 | 661.00 | 646.00 | 539.00 | 611.00 |
| Borrowings, current | 1,512.00 | 1,211.00 | 1,435.00 | 1,709.00 | 2,060.00 | 2,048.00 | 1,611.00 | 1,786.00 |
| Trade payables | 1,117.00 | 711.00 | 997.00 | 1,051.00 | 1,058.00 | 958.00 | 1,014.00 | 1,252.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 243.00 | 994.00 | 474.00 | 666.00 | 57.00 | 602.00 | 1,093.00 | 1,624.00 |
| Net cash from investing activities | -415.00 | -996.00 | -405.00 | -822.00 | -254.00 | -682.00 | -477.00 | -1,089.00 |
| Net cash from financing activities | 148.00 | -27.00 | -48.00 | 250.00 | 99.00 | 39.00 | -668.00 | -525.00 |
| Purchase of property, plant and equipment | 416.00 | 990.00 | 364.00 | 678.00 | 262.00 | 641.00 | 489.00 | 1,070.00 |
| Net increase in cash | -25.00 | -30.00 | 21.00 | 93.00 | -96.00 | -39.00 | -50.00 | 13.00 |
| con:CFO.BEFORE_TAX | 333.00 | 1,132.00 | 533.00 | 590.00 | -23.00 | 476.00 | 1,047.00 | 1,672.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | -145.00 | 0.00 | -175.00 | -99.00 | -210.00 | -89.00 | -165.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 90.00 | 285.00 | 58.00 | 105.00 | 39.00 | 138.00 | 94.00 | 294.00 |
| con:CF_OTHER.OPERATING | 0.00 | 2.00 | 0.00 | 5.00 | 20.00 | 53.00 | 52.00 | 81.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 3.00 | 1.00 | 2.00 | 3.00 | 100.00 | 3.00 | 7.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | -72.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 22.00 | 48.00 | 80.00 | 0.00 | 0.00 | 0.00 | 27.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 105.00 | 9.00 | 49.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 27.20 | 27.20 | 27.20 | 27.19 | 27.19 | 27.18 | 27.18 | 27.62 | 27.62 | 27.59 | 0.28 | 0.27 | 0.27 | 0.27 |
| Domestic institutions | 9.74 | 10.35 | 11.01 | 11.14 | 11.77 | 13.56 | 13.05 | 12.74 | 11.77 | 11.94 | 0.12 | 0.12 | 0.14 | 0.14 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 7.78 | 0.09 | 0.09 | 0.11 | 0.10 |
| Insurance companies | 4.15 | 4.99 | 5.41 | 5.19 | 4.75 | 3.94 | 4.06 | 4.08 | 3.63 | 2.76 | 0.02 | 0.02 | 0.01 | 0.02 |
| Foreign institutions | 22.42 | 22.52 | 24.03 | 25.39 | 25.97 | 25.67 | 26.08 | 25.56 | 25.52 | 25.70 | 0.26 | 0.27 | 0.26 | 0.28 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Public | 72.80 | 72.80 | 72.80 | 72.81 | 72.81 | 72.82 | 72.82 | 72.38 | 72.38 | 72.41 | 0.72 | 0.73 | 0.73 | 0.73 |
| Non-institutional | 40.64 | 39.93 | 37.76 | 36.29 | 35.07 | 33.59 | 33.69 | 34.08 | 35.09 | 34.77 | 0.35 | 0.34 | 0.33 | 0.31 |
| Shares outstanding | 538650925 | 538650925 | 538650925 | 538965858 | 538965858 | 539159314 | 539159314 | 539252491 | 539252491 | 539824899 | 539824899 | 539856582 | 539856582 | 540249583 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Laurus Synthesis Private Limited | Subsidiary Company | Any other transaction, Interest received, Loan, Purc | 1,292,300,000.00 | 12 |
| Laurus Generics Inc | Step-down subsidiary company | Any other transaction, Sale of goods or services | 1,050,400,000.00 | 5 |
| Sriam Labs Private Limited | Subsidiary Company | Any other transaction, Purchase of goods or services | 223,500,000.00 | 6 |
| NSN Investments | Enterprise over which Key Manageme | Any other transaction | 69,000,000.00 | 3 |
| Laurus Bio Private Limited | Subsidiary Company | Any other transaction, Interest received, Loan, Purc | 66,100,000.00 | 5 |
| Dr. C. Satyanarayana | Key Management Personnel | Remuneration | 66,000,000.00 | 1 |
| Dr. C. Satyanarayana on behalf of M/S. NSN Holdings | Promoter | Dividend paid | 49,700,000.00 | 1 |
| Ethan Energy India Private Limited | Associate Company | Purchase of goods or services | 41,200,000.00 | 1 |
| Laurus Charitable Trust | Enterprise over which Key Manageme | Any other transaction | 30,500,000.00 | 1 |
| Laurus Holdings Limited | Subsidiary Company | Any other transaction | 28,600,000.00 | 2 |
| Mr. V.V. Ravi Kumar | Key Management Personnel | Any other transaction, Dividend paid, Remuneration | 23,200,000.00 | 3 |
| Dr. C.V.Lakshmana Rao | Key Management Personnel | Dividend paid, Remuneration | 20,200,000.00 | 2 |
| Chemiasoft Private Limited | Enterprise over which Key Manageme | Purchase of goods or services | 17,800,000.00 | 1 |
| Mr. C. Narasimha Rao | Relative of Key Management Personn | Remuneration | 9,500,000.00 | 1 |
| Mr. C. Krishna Chaitanya | Key Management Personnel | Remuneration | 8,100,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-30 | Q1FY27 | Relations., Satyanarayana Chava:, innovators., portfolio. | Read the call |
| 2026-05-05 | Q4FY26 | Read the call | |
| 2026-01-28 | Q3FY26 | LAURUS LABS LIMITED, LIMITED | Read the call |
| 2025-10-28 | Q2FY26 | LIMITED | Read the call |
| 2025-07-29 | Q1FY26 | Read the call | |
| 2025-04-28 | Q4FY25 | Read the call | |
| 2025-01-29 | Q3FY25 | Read the call | |
| 2024-10-29 | Q2FY25 | Read the call | |
| 2024-07-29 | Q1FY25 | CFO, LAURUS LABS LIMITED, LAURUS LABS LIMITED | Read the call |
| 2024-04-30 | Q4FY24 | CFO, LAURUS LABS LIMITED, LAURUS LABS LIMITED | Read the call |
| 2024-01-30 | Q3FY24 | Read the call | |
| 2023-10-25 | Q2FY24 | Read the call | |
| 2023-08-01 | Q1FY24 | CHIEF FINANCIAL OFFICER, EXECUTIVE OFFICER, LIMITED. | Read the call |
| 2023-05-03 | Q4FY23 | Read the call | |
| 2023-02-04 | Q3FY23 | Read the call | |
| 2022-10-25 | Q2FY23 | CEO. – LAURUS LABS, CFO. – LAURUS LABS | Read the call |
| 2022-08-02 | FYFY23 | LIMITED | Read the call |
| 2022-05-05 | Q4FY22 | BROKING, CEO, LAURUS LABS, LABS | Read the call |
| 2022-02-02 | Q3FY22 | Read the call | |
| 2021-11-02 | Q2FY21 | Read the call | |
| 2021-08-03 | Q1FY22 | Read the call | |
| 2021-05-05 | Q4FY21 | LIMITED | Read the call |
| 2021-02-05 | Q3FY21 | Read the call | |
| 2020-11-09 | Q2FY21 | Read the call | |
| 2020-08-05 | Q1FY21 | Read the call | |
| 2020-05-09 | Q4FY20 | Read the call | |
| 2020-02-10 | Q3FY20 | Read the call | |
| 2019-11-07 | Q2FY20 | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q3FY26 | Q4FY20 | Q4FY21 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Some of the notable progress I wish to highlight, we made significant investments in CAPEX so far in peptide development and manufacturing infrastruct… | On a capex spend we invested about Rs.230 Crores in the year. | On the CAPEX front, we have incurred around Rs.700 crores, which includes the capital work- Laurus Labs Limited April 30, 2021 in progress. | So, so my first question was with regards to CapEx. | Will there be a reduction in the capex intensity in the business? | On the CAPEX front, we invested close to Rs. | On the capex front, we invested close to INR211 crores in the quarter and INR659 crores for the full year. | Currently, we are managing several capex growth projects, which will be executed in the next 2 years. |
| Capital allocation | — | We have declared a final dividend of Rs.1 per share this is apart from Rs.1.50 per share as an interim dividend in March 2020. | So, based on the performance of the company we have declared a third interim dividend of 80 paise per share. | Second on the strategy side, so if you could share more color on the sterile R&D and also when we had done this minority acquisition in the ImmunoACT … | — | — | Krka JV collaboration is progressing well and land acquisition completed. | — |
| Costs | Nitin, actually what happened, actually we suffered for a few quarters because of the steep price reduction but that we could able to recover those th… | One good thing is most of the Chinese factories came back to normal capacity but the freight by sea or by air is becoming challenging, the air freight… | — | Some improvement will come from softening of the raw material prices and solvent prices, but we don't foresee the API prices and formulary prices goin… | At least it's a good business because we know the raw material cost, our partner also knows the raw material cost, we are not changing process. | We are accelerating, focusing on increased efficiency, sourcing, and cost improvements to mitigate inflation and price pressures. | — | However, increasing geopolitical disruptions may impact raw material availability and logistics, potentially creating a near-term pressure on OTIF per… |
| Debt and cash | And this would be largely done with keeping net debt at similar numbers? | Right and just the last one, you do not see any working capital challenges I mean not challenges from our balance sheet perspective but a stress in an… | — | When I look at the balance sheet, there's a sharp increase in other current liabilities and I am trying to understand what has led to this and the ope… | — | Going ahead, we are focusing on gradually returning to growth and prioritizing investment in high value segment along with improvement in the working … | So we don't expect significant operational deleverage in the financial year '26, because we are not adding new sites. | So we are at the border of leverage or deleverage. |
| Demand | Pipeline momentum has remained very healthy with well-balanced mix of big pharma clientele and also mid- and small-size biotechs. | With the healthy outlook and order book, we continue to invest in our FDF infrastructure. | Due to the increase in the demand for third-party API sales, we are still expanding the API capacity to serve the existing demand from the customers. | So we haven't seen any significant price drops from FY 2021 remain constant, FY 22 was the year where we saw a drop, but I don't think FY 23 will have… | And you are talking of the cost improvement and the technology improvement, ongoing projects and pipeline and the new growth launches. | We continue to have diverse portfolios and pipelines across ARVs, Cardiovascular, Diabetes, CNS, and GI. | While we continue to work towards realizing the potential of the late-stage pipeline, we are also strengthening our focus to broaden the project funne… | In 2026, we significantly accelerated our performance, reflecting sustained demand in technology-driven commercial offerings. |
| Guidance | January 23, 2026 numbers are also sustainable in the long run, may not be in Q4 this year and Q1 next year but eventually we expect to do well there a… | This will be done and the expanded capacity available during the current financial year FY2021. We have also undertaken a Brownfield expansion project… | In the medium-term, what we expect this division to be Laurus Labs Limited April 30, 2021 vertically integrated into offering a contract development a… | In FY 23 we expect our divisions will grow, but percentages broadly will remain similar, what it means, that means we have opportunities to grow API b… | And going forward for the overall ARV business, in the past year, there's been guidance of around INR2,500 crores of revenues for the API plus the FDF… | So, when can we expect it to start, sir? | We have executed on multiple integrated CMO contract in the year and for some new contracts We expect increased sales to continue in future quarters, … | Lastly, we are also spending on formulation facility under our KRKA joint venture in Hyderabad, and we expect Phase 1 will be completed by mid-2027. |
| Margin | 2,092 crore which is similar range of quarter ended September and debt to EBITDA has further decreased to around 1.2x On the capital allocation front,… | Our gross margin continued to show an improvement with around 50%. | With a better product mix, gross margin improved significantly; now, it is a 55% gross margin. | Like you said ARV the price pressure, which is new base, even solvent prices, I don't know whether it is coming down, so that way this should be the n… | And the 4Q EBITDA margin level, is that a good base to work with? | We are prioritizing efforts to improve our operating margin, particularly increasing asset utilization across our network and delivering on a few of o… | The company achieved a revenue of INR5,554 crores, gross margins were healthy and maintained around 55% range, and EBITDA margins expanded by 4 percen… | Gross margins were healthy and maintained around 60% range and EBITDA margins expanded by 6.7 percentage points to 26.8%. |
| People | Okay, so that means you are almost at the full capacity utilization? | Sir with respect to like we are looking at this year as phenomenal year as far as formulation is concerned, I do not want specific number into it but … | Our ROCE is 40% on annualized basis due to operational leverage and higher asset utilization. | My first question is on Laurus Bio, so the INR 35 crore revenue for the quarter, so very impressive ramp up there, trying to understand how much of th… | And our plants can potentially run at 100% or is the peak utilization like 85%? | These launches will support better asset utilization. | Our ROCE improved from 6.4% to 9.7%, but of course still it is at a lower, close to double digit, but it will improve further based on the asset utili… | Just a quick follow-up on that one, Dr. Satya, for the capacities we commissioned about, let's say, 2, 3 years back, where is the utilization level at… |
| Pricing | First question is, both for CDMO as well as for API and FDF business, Q-on-Q and Y-o-Y if you can just highlight is there anything with respect to vol… | Which means that in volumes we cannot do much of this thing it will be pricing that will drive the growth? | We have not taken any price hike in FY'21. | Unfortunately, we can't give any details on our contract product, our pricing, and the quantum of the order also, see we gave what we can give and wha… | As we implement some measures in process improvements, manufacturing cost improvement, purchase pricing improvement, these margins will improve. | We also expect pricing headwinds in the parts of the API portfolio, but which we believe will offset from volume increases and continued cost improvem… | You said that the market is impacted by the pricing pressure from the IRA. | I mean what does it mean for the steady-state economic model for Laurus, I mean, in terms of utilization, yields, pricing structure and customer conce… |
| Revenue growth | The revenues from the generic division have continued to perform well, reporting growth of 37% to Rs. | Thank you everyone and a very warm welcome to results conference call and business highlights for Q4 FY2020. Our Q4 FY2020 revenues stood at Rs.840 Cr… | We're happy to share that in FY21 Laurus Labs has done exceptionally well; our 4Q revenue stood at Rs.1,412 crores, showcasing a robust growth of 68% … | We are seeing the revenue growth to be seasonal in the Q4 for like for three years. so do we say that the business has seasonality or is it just becau… | Not only looking at numbers here but if you could just suggest whether this is in terms of top line or bottom line. | In the Bio division, the full year reported stronger than expected growth of Rs. | The growth was mainly driven by several mid- to late-stage NCE deliveries and steady increase in sales from new manufacturing assets, which was bought… | The company's revenues were INR6,813 crores with a growth of 23% over previous year. |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2026-07-30 | Q1FY27 | Satyanarayana Chava: | But we expect ROCE will continue to grow from last year, it is 17.7%, this year it is 19% something. |